Variant Phenotype Annotation
证据URL
https://www.pharmgkb.org/variantAnnotation/1444933870
总结
CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizers phenotype) are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *5/*10 + *10/*14 (assigned as intermediate metabolizers phenotype) .